Keystone Clinical Studies LLC

1. Eisai Inc. $4,671,291 369 payments
2. Janssen Research & Development, LLC $3,056,274 147 payments
3. Sage Therapeutics, Inc. $907,027 72 payments
4. Teva Pharmaceuticals USA, Inc. $432,806 18 payments
5. AbbVie, Inc. $217,584 30 payments
6. Allergan Inc. $172,502 31 payments
7. Otsuka Pharmaceutical Development & Commercialization, Inc. $91,787 2 payments
8. Neurocrine Biosciences, Inc. $42,640 2 payments
9. Takeda Pharmaceuticals U.S.A., Inc. $34,864 5 payments
10. H. Lundbeck A S $4,600 1 payment

1. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $2,930,561 95 payments
2. A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease $1,732,837 84 payments
3. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $1,269,367 57 payments
4. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $648,082 55 payments
5. A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $536,515 33 payments
6. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $508,926 192 payments
7. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $436,855 24 payments
8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $432,806 18 payments
9. A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid $209,995 18 payments
10. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $158,960 12 payments

1. Other $34,864 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.